OBJECTIVE: The aim of this study was to appropriately plan for rollout and monitor impact of oral preexposure prophylaxis (PrEP). It is important to understand PrEP continuation and come to a consensus on how best to measure PrEP continuation. This study reviews data on PrEP continuation to document how it is reported, and to compare continuation over time and across populations. DESIGN: A systematic review and meta-analysis. METHODS: We searched MEDLINE, Embase and Global Health and reviewed abstracts from HIV conferences from 2017 to 2018 for studies reporting primary data on PrEP continuation. Findings were summarized along a PrEP cascade and continuation was presented by population at months 1, 6 and 12, with random-effects meta-analysis. RESULTS: Of 2578 articles and 596 abstracts identified, 41 studies were eligible covering 22 034 individuals. Continuation data were measured and reported inconsistently. Results showed high discontinuation at month 1 and persistent discontinuation at later time points in many studies. Pooled continuation estimates were 66% at month 1 [n = 5348; 95% confidence interval (95% CI): 48-82], 63% at month 6 (n = 13 629; 95% CI: 48-77) and 71% at month 12 (n = 14 933; 95% CI: 60-81; higher estimate than previous timepoints due to inclusion of different studies). Adequate data were not available to reliably compare estimates across populations. CONCLUSION: This review found that discontinuation at one month was high, suggesting PrEP initiations may be a poor measure of effectiveness. Continuation declined further over time in many studies, indicating existing cross-sectional indicators may not be adequate to understand PrEP use patterns. Studies do not measure continuation consistently, and consensus is needed.
OBJECTIVE: The aim of this study was to appropriately plan for rollout and monitor impact of oral preexposure prophylaxis (PrEP). It is important to understand PrEP continuation and come to a consensus on how best to measure PrEP continuation. This study reviews data on PrEP continuation to document how it is reported, and to compare continuation over time and across populations. DESIGN: A systematic review and meta-analysis. METHODS: We searched MEDLINE, Embase and Global Health and reviewed abstracts from HIV conferences from 2017 to 2018 for studies reporting primary data on PrEP continuation. Findings were summarized along a PrEP cascade and continuation was presented by population at months 1, 6 and 12, with random-effects meta-analysis. RESULTS: Of 2578 articles and 596 abstracts identified, 41 studies were eligible covering 22 034 individuals. Continuation data were measured and reported inconsistently. Results showed high discontinuation at month 1 and persistent discontinuation at later time points in many studies. Pooled continuation estimates were 66% at month 1 [n = 5348; 95% confidence interval (95% CI): 48-82], 63% at month 6 (n = 13 629; 95% CI: 48-77) and 71% at month 12 (n = 14 933; 95% CI: 60-81; higher estimate than previous timepoints due to inclusion of different studies). Adequate data were not available to reliably compare estimates across populations. CONCLUSION: This review found that discontinuation at one month was high, suggesting PrEP initiations may be a poor measure of effectiveness. Continuation declined further over time in many studies, indicating existing cross-sectional indicators may not be adequate to understand PrEP use patterns. Studies do not measure continuation consistently, and consensus is needed.
Authors: Maria Pyra; Russell Brewer; Laura Rusie; Jeanelle Kline; India Willis; John Schneider Journal: J Acquir Immune Defic Syndr Date: 2022-02-01 Impact factor: 3.771
Authors: Jing Zhang; Chunyan Li; Junjie Xu; Zhili Hu; Sarah E Rutstein; Joseph D Tucker; Jason J Ong; Yongjun Jiang; Wenqing Geng; Sarah T Wright; Myron S Cohen; Hong Shang; Weiming Tang Journal: Lancet HIV Date: 2022-04 Impact factor: 16.070
Authors: Fernandos K Ongolly; Annabel Dolla; Kenneth Ngure; Elizabeth M Irungu; Josephine Odoyo; Elizabeth Wamoni; Kathryn Peebles; Kenneth Mugwanya; Nelly R Mugo; Elizabeth A Bukusi; Jennifer Morton; Jared M Baeten; Gabrielle O'Malley Journal: J Acquir Immune Defic Syndr Date: 2021-05-01 Impact factor: 3.771
Authors: Thibaut Vanbaelen; Anke Rotsaert; Bart K M Jacobs; Eric Florence; Chris Kenyon; Bea Vuylsteke; Marie Laga; Reyniers Thijs Journal: AIDS Patient Care STDS Date: 2022-04 Impact factor: 5.944
Authors: Andrew N Phillips; Anna Bershteyn; Paul Revill; Loveleen Bansi-Matharu; Katharine Kripke; Marie-Claude Boily; Rowan Martin-Hughes; Leigh F Johnson; Zindoga Mukandavire; Lise Jamieson; Gesine Meyer-Rath; Timothy B Hallett; Debra Ten Brink; Sherrie L Kelly; Brooke E Nichols; Eran Bendavid; Edinah Mudimu; Isaac Taramusi; Jennifer Smith; Shona Dalal; Rachel Baggaley; Siobhan Crowley; Fern Terris-Prestholt; Peter Godfrey-Faussett; Irene Mukui; Andreas Jahn; Kelsey K Case; Diane Havlir; Maya Petersen; Moses Kamya; Catherine A Koss; Laura B Balzer; Tsitsi Apollo; Thato Chidarikire; John W Mellors; Urvi M Parikh; Catherine Godfrey; Valentina Cambiano Journal: Lancet HIV Date: 2022-05 Impact factor: 16.070
Authors: Ivana Beesham; Leila E Mansoor; Dvora L Joseph Davey; Thesla Palanee-Phillips; Jenni Smit; Khatija Ahmed; Pearl Selepe; Cheryl Louw; Mandisa Singata-Madliki; Philip Kotze; Renee Heffron; Urvi M Parikh; Lubbe Wiesner; Helen Rees; Jared M Baeten; Mags Beksinska Journal: J Acquir Immune Defic Syndr Date: 2022-06-09 Impact factor: 3.771
Authors: Robin Schaefer; Pedro Henrique Amparo da Costa Leite; Ronaldo Silva; Quarraisha Abdool Karim; Christopher Akolo; Carlos F Cáceres; Inês Dourado; Kimberly Green; Anita Hettema; Elske Hoornenborg; Smarajit Jana; Bernhard Kerschberger; Hally Mahler; Sindy Matse; Hamish McManus; Jean-Michel Molina; Sushena Reza-Paul; Iskandar Azwa; Maryam Shahmanesh; Doug Taylor; Hamid Vega-Ramirez; Valdiléa G Veloso; Rachel Baggaley; Shona Dalal Journal: Lancet HIV Date: 2022-03-07 Impact factor: 16.070